Annexon, Inc. (ANNX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Company: Annexon, Inc.
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Overview: Annexon is a clinical-stage biopharmaceutical company developing therapies targeting neuroinflammation via the classical complement pathway. The company has no approved products and generates no revenue. Key programs include tanruprubart for Guillain-Barré Syndrome (GBS), vonaprument for Geographic Atrophy (GA), and ANX1502 for autoimmune indications.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(54,922) | $(34,824) | $(158,434) | $(89,610) |
| Net Loss Per Share (Basic/Diluted) | $(0.37) | $(0.25) | $(1.08) | $(0.68) |
| Operating Expenses | $57,018 | $39,442 | $166,149 | $101,594 |
| Cash & Cash Equivalents | $139,419 | $49,498 | (Balance Sheet Data) | |
| Short-term Investments | $49,302 | $262,519 | ||
| Total Liquidity (Cash + ST Inv) | $188,721 | $312,017 | (As of Sept 30, 2025) | |
| Accumulated Deficit | $(869,133) | $(662,109) | (As of Sept 30, 2025) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 45% in Q3 2025 ($57.0M) compared to Q3 2024 ($39.4M). This was driven by a 65% increase in R&D expenses ($49.7M vs. $30.1M), primarily due to higher clinical trial costs for the vonaprument Phase 3 ARCHER II trial and the tanruprubart FORWARD study, as well as increased contract manufacturing for regulatory submissions.
- Decreased G&A: General and administrative expenses decreased 22% in Q3 2025 ($7.3M vs. $9.3M) due to reduced consulting and professional services costs.
- Reduced Interest Income: Interest and other income dropped 55% in Q3 2025 ($2.1M vs. $4.6M) due to lower average cash and investment balances.
- Liquidity Shift: While cash and cash equivalents increased significantly from $49.5M to $139.4M, short-term investments decreased from $262.5M to $49.3M, resulting in a net decrease in total liquidity of approximately $123M compared to the prior year period.
Guidance, Outlook, and Risks
- Cash Runway: Management projects that existing cash and short-term investments ($188.7M) will fund operations into late Q1 2027.
- Regulatory Milestones:
- Tanruprubart (GBS): Marketing Authorization Application (MAA) submission to the EMA is expected in January 2026. Dialogue with the FDA regarding the Biologics License Application (BLA) is ongoing.
- Vonaprument (GA): Enrollment for the Phase 3 ARCHER II trial was completed in July 2025. Topline data is expected in the second half of 2026.
- ANX1502: Proof-of-concept study in cold agglutinin disease is ongoing, with an update expected in 2026.
- Capital Requirements: The company anticipates needing substantial additional financing to achieve its goals. Failure to secure funding could force delays or termination of programs.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approval timelines (particularly regarding data from non-US trials for GBS), reliance on third-party manufacturers, and the need for future capital raises which may result in dilution.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $188.7M liquidity position against the projected runway into late Q1 2027, considering the accelerating R&D spend.
- Regulatory Strategy for GBS: Confirm the status of FDA discussions regarding the acceptance of data from Southeast Asian trials for the tanruprubart BLA submission.
- Phase 3 Trial Status: Monitor the progress and data readout timeline for the vonaprument ARCHER II trial (expected H2 2026).
- Financing Plans: Assess the company's strategy for raising additional capital, including the utilization of the remaining $81.2M under the 2024 ATM program.
- Warrant Dilution: Note the existence of 38.5M pre-funded warrants and 6.9M common warrants, which represent significant potential dilution if exercised.